ICICI Direct: Sun Pharma’s Significant Beat On All Fronts In Q2

Sun Pharma’s ebitda margin expanded 361 bps year-on-year to 25.6% in Q2 due to a better product mix and lower other expenditure.

ICICI Direct

04 Nov 2020, 05:34 PM IST

The Sun Pharmaceutical Industries Ltd. logo sits on a sign on pharmaceutical and medical supply storage racks. (Photographer: Jasper Juinen/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct: Sun Pharma’s Significant Beat On All Fronts In Q2

Sun Pharma’s ebitda margin expanded 361 bps year-on-year to 25.6% in Q2 due to a better product mix and lower other expenditure.

Choose a plan